KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Current Deferred Revenue (2016 - 2025)

Novavax has reported Current Deferred Revenue over the past 16 years, most recently at $140.1 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $140.1 million for Q4 2025, down 87.52% from a year ago — trailing twelve months through Dec 2025 was $140.1 million (down 87.52% YoY), and the annual figure for FY2025 was $140.1 million, down 87.52%.
  • Current Deferred Revenue for Q4 2025 was $140.1 million at Novavax, down from $501.4 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for NVAX hit a ceiling of $1.6 billion in Q4 2021 and a floor of $28.0 million in Q1 2025.
  • Median Current Deferred Revenue over the past 5 years was $994.9 million (2023), compared with a mean of $944.3 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 26331.1% in 2021 and later crashed 97.41% in 2025.
  • Novavax's Current Deferred Revenue stood at $1.6 billion in 2021, then plummeted by 65.56% to $549.6 million in 2022, then soared by 57.13% to $863.5 million in 2023, then increased by 29.92% to $1.1 billion in 2024, then crashed by 87.52% to $140.1 million in 2025.
  • The last three reported values for Current Deferred Revenue were $140.1 million (Q4 2025), $501.4 million (Q3 2025), and $500.0 million (Q2 2025) per Business Quant data.